10×10 Tablets
Overview
TELSHIV-TRIO is the definitive solution in the management of treated but uncontrolled hypertensives. This triple-combination tablet — Telmisartan 40mg (Micronized) + Amlodipine 5mg + Hydrochlorothiazide 12.5mg — delivers Comprehensive 24-Hour BP Control through potent synergistic action across three complementary antihypertensive pathways.
Clinical data demonstrates superior Systolic BP reduction with triple therapy versus mono and dual therapy, with TELSHIV-TRIO addressing the full RAAS, calcium channel, and diuretic axes simultaneously. Micronization of Telmisartan ensures enhanced dissolution and consistent bioavailability.
Indications
- Treated but uncontrolled hypertension — inadequate BP response on mono or dual therapy
- Hypertension in patients with Type 2 Diabetes Mellitus
- Hypertension with established cardiovascular disease
- High cardiovascular risk requiring rapid attainment of BP targets
- Replacement therapy for patients stabilised on all three components separately
Triple Mechanism — Synergistic BP Control
TELMISARTAN (ARB)
- Selectively blocks AT1 angiotensin II receptors — prevents vasoconstriction and aldosterone secretion
- 24-hour BP coverage due to long half-life (~24 hours)
- Micronized formulation enhances dissolution rate and bioavailability
AMLODIPINE (CCB)
- Inhibits voltage-gated L-type calcium channels in vascular smooth muscle
- Causes arterial vasodilation without negative inotropic effects
- Low cough incidence — key advantage over ACE inhibitors
HCTZ — DIURETIC
- Acts on distal convoluted tubule to inhibit Na+/Cl- co-transporter
- Promotes natriuresis and diuresis — reduces plasma volume and cardiac preload
- Addresses the volume-overload component common in uncontrolled hypertensives
Dosage & Administration
- Standard dose: 1 tablet once daily, at the same time each day
- Can be taken with or without food
- Elderly (>65 years): No dose adjustment required; initiate with monitoring
- Renal impairment (CrCl < 30): Use with caution; HCTZ component may be less effective
- Hepatic impairment: Telmisartan AUC increased; use with caution in moderate impairment
Contraindications
- Hypersensitivity to telmisartan, amlodipine, sulfonamides (HCTZ), or any excipient
- Pregnancy (all trimesters) — ARBs are teratogenic
- Severe hepatic impairment (Child-Pugh Class C)
- Biliary obstructive disorders (telmisartan primarily biliary excreted)
- Anuria or severe renal failure (CrCl < 30 mL/min)
- Concomitant use with aliskiren in diabetic patients
- Refractory hypokalaemia or hyponatraemia
